Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 3.0x - 3.3x | 3.1x |
| Selected Fwd Ps Multiple | 0.5x - 0.6x | 0.5x |
| Fair Value | $0.46 - $0.51 | $0.49 |
| Upside | 25.6% - 38.9% | 32.3% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| 4Front Ventures Corp. | - | OTCPK:FFNT.F |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| ProPhase Labs, Inc. | - | NasdaqCM:PRPH |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT.F | HRMY | EOLS | TARS | BIOE | PRPH | |||
| OTCPK:FFNT.F | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | NasdaqCM:PRPH | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 91.7% | 160.2% | 50.1% | NM- | -17.1% | -7.3% | ||
| 3Y CAGR | 19.1% | 32.8% | 38.8% | 47.5% | -28.5% | -55.9% | ||
| Latest Twelve Months | -27.5% | 20.6% | 25.4% | 449.0% | -37.2% | -67.6% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | 5.6% | -83.6% | -262.7% | -186.6% | -170.0% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -778.9% | NA | -46.8% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -63.2% | -483.3% | -731.5% | ||
| Latest Twelve Months | -46.6% | 20.5% | -20.4% | -44.9% | -476.3% | -832.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -13.4x | 7.1x | -23.8x | -13.6x | -22.4x | -1.0x | ||
| Price / LTM Sales | 0.0x | 2.7x | 2.2x | 7.7x | 25.3x | 2.6x | ||
| LTM P/E Ratio | -0.1x | 13.0x | -10.5x | -17.2x | -5.3x | -0.3x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.0x | 2.7x | 25.3x | |||||
| Historical LTM P/S Ratio | 1.1x | 2.8x | 8.7x | |||||
| Selected Price / Sales Multiple | 3.0x | 3.1x | 3.3x | |||||
| (x) LTM Sales | 6 | 6 | 6 | |||||
| (=) Equity Value | 17 | 18 | 19 | |||||
| (/) Shares Outstanding | 41.5 | 41.5 | 41.5 | |||||
| Implied Value Range | 0.42 | 0.44 | 0.46 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.42 | 0.44 | 0.46 | 0.37 | ||||
| Upside / (Downside) | 12.6% | 18.5% | 24.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT.F | HRMY | EOLS | TARS | BIOE | PRPH | |
| Value of Common Equity | 0 | 1,981 | 593 | 1,805 | 9 | 15 | |
| (/) Shares Outstanding | 916.4 | 57.4 | 64.5 | 42.0 | 38.0 | 41.5 | |
| Implied Stock Price | 0.00 | 34.50 | 9.19 | 42.95 | 0.23 | 0.37 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.00 | 34.50 | 9.19 | 42.95 | 0.23 | 0.37 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |